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Recent evidence shows that specific fatty acids affect cell metabolism, modifying the balance between fatty acid oxidation and lipogenesis. These
effects may have important implications in addressing the present epidemic of nutrition-related chronic disease. Intake of dietary saturated and n-6
PUFA have increased while n-3 fatty acid intake has decreased. Obesity, type 2 diabetes and insulin resistance are highly prevalent, and both are
strongly related to disorders of lipid metabolism characterized by an increased plasma and intracellular fatty acid availability. Thus, it has been
hypothesized that change in the quality of dietary fat supply is able to modify the degree of insulin sensitivity. Animal studies provide support for
this notion. However, there is limited human data either from normal or diabetic subjects. This review aims to analyse human studies that address
this question. To this purpose, the experimental design, dietary compliance, insulin-sensitivity method used and confounding variables are
discussed in order to identify the role of dietary fat quality as a risk factor for insulin resistance. Most studies (twelve of fifteen) found no
effect relating to fat quality on insulin sensitivity. However, multiple study design flaws limit the validity of this conclusion. In contrast, one
of the better designed studies found that consumption of a high-saturated-fat diet decreased insulin sensitivity in comparison to a high-monoun-
saturated-fat diet. We conclude that the role of dietary fat quality on insulin sensitivity in human subjects should be further studied, using exper-
imental designs that address the limitations of existing data sets.
Insulin sensitivity: Fat quality: Lipid metabolism
Diet and physical activity patterns have changed drastically in
both industrialized and developing countries together with a
rapid increase in nutrition-related chronic diseases such as
obesity, CVD and type 2 diabetes(1). Physical activity has
decreased while total energy, fat and refined carbohydrate con-
sumption have increased in virtually all age groups(1). By now
most recognize that sustained changes in diet and physical
activity, which promote better health, are difficult to achieve.
Nutritionists have focused on dietary characteristics that could
contribute to the adverse consequences of obesity, for instance
fat quality that could be amenable to change, manipulating
dietary ingredients or the fatty acid (FA) composition of the
traditional fats consumed.
Fat ingested is a blend of different FA, no source is pure.
The types of fat consumed are SFA, MUFA and PUFA. The
latter are separated into two classes based on the presence
of unsaturated bonds in positions n-6 or n-3. Simopoulos(2)
has described major time-related trends in total and SFA
intake over the past two centuries; an increase in the total
and in the SFA consumed, while the proportion of n-3:n-6
PUFA has decreased significantly. These changes have
proven to be important in the risk of CVD(3). Convincing
evidence exists to support the notion that higher consumption
of linoleic, oleic, and n-3 PUFA (a-linolenic, EPA and DHA)
FA and lower intake of SFA (myristic and palmitic acids)
and trans-FA reduce the risk of CVD. Differential capacity
to modify plasma LDL-cholesterol, blood pressure, cardiac
function, endothelial function and vascular reactivity, as well
as different influence on platelet aggregation and inflammation
are the cellular basis to explain the well-documented relation-
ship between dietary fat quality and CVD(4).
Incidence of type 2 diabetes also might be modified as a
function of dietary FA quality, since several studies in animals
have demonstrated a differential impairment in the degree of
insulin sensitivity (IS) after feeding with SFA, n-6 PUFA or
n-3 PUFA(5,6). Impaired IS is a main risk factor for type 2 dia-
betes, hence strategies to prevent a reduction in IS may have a
large impact on reducing populations affected with type 2
diabetes. In human subjects, several studies have been per-
formed to evaluate the role of dietary FA quality on IS(7 – 10)
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although currently more published studies report no effect of
dietary fat quality on this variable. This review analyses
human studies where the effects of dietary fat quality on IS
have been evaluated. Special attention was given to the meth-
odological aspects of each study. We conducted a literature
search in PubMed for randomized clinical trials in human sub-
jects published until 31 August 2007. These articles were
identified with the following key words: fatty acid type and
insulin. Other articles not identified after this first search
were found using the Related Articles option available in
Medline. Bibliographies of primary references were used to
identify additional relevant studies.
Effect of fatty acid quality on insulin sensitivity
In human subjects, multiple epidemiological studies and inter-
vention trials have assessed the role of dietary fat quality on
IS. However, evidence to support a contrasting effect on IS
was judged only as possible by the FAO/WHO expert group
in a recent report on Diet, Nutrition and Prevention of Chronic
Disease (1). Since the convincing and probable categories were
required to establish a recommendation, the role of FA quality
in ameliorating the risk of type 2 diabetes was not incorpor-
ated in the guidance. This section will review the descriptive
and intervention human studies published to date and the mul-
tiple methodological issues that should be considered in the
interpretation of the results.
Descriptive studies
In general, epidemiological studies report that dietary content
of SFA is directly, and unsaturated fat is inversely, associated
with the incidence of type 2 diabetes or impaired IS, respect-
ively(8,9). For example, in a 14-year follow-up study conducted
in women(11), an increase by 5 % of total energy intake as SFA
or MUFA did not modify the relative risk of type 2 diabetes;
however, the same relative increase as PUFA significantly
reduced the relative risk to 0·63 (95 % CI 0·53, 0·76) once
adjusted by relevant confounders. On the other hand, a
cross-sectional study found no association between dietary
FA quality with IS (by Minimal Model) after adjusting for
critical confounders(12).
Interpretation of these results is complicated further by the
close correlation between dietary FA in specific foods. For
example animal fat consumption increases both SFA and
MUFA; even within the SFA the effect of palmitic and stearic
acids may be different since the latter is rapidly converted to
oleic acid(13). Inaccurate dietary assessment methods and
inadequate FA food composition provide added complexity
to the analysis. This has led to the measurement of FA com-
position of tissues or plasma lipid fractions as potential
improved markers of dietary exposure.
Folsom et al. (14) found that an increase in SFA in plasma
phospholipids equivalent to the interquartile range elevated
the odds for hyperinsulinaemia to 2·4-fold (95 % CI 1·7,
3·3), after adjusting for BMI and fasting glycaemia. On the
other hand, Pelika´nova´ et al. (15) found a higher proportion
of arachidonic acid in plasma phospholipids from type 2 dia-
betic compared to healthy subjects. In addition, in healthy
individuals an inverse correlation between insulin-stimulated
glucose disposal rate and serum phospholipid SFA:linoleic
acid ratio was observed, which explained about one-third of
the IS variance in this group.
Information of greater relevance may be obtained from
skeletal muscle given its critical role in insulin-stimulated glu-
cose uptake(16). Borkman et al. (17) found in healthy subjects
that the proportion of PUFA with twenty to twenty-two car-
bons in skeletal muscle phospholipids was directly associated
to IS. On the other hand, Manco et al. (18) observed in muscle
TAG from obese individuals, a lower degree of unsaturation in
comparison to lean subjects. In addition, the combination of
increased muscle TAG and palmitate content were the main
determinants of impaired IS. These studies suggest that dietary
fat quality may be a relevant factor in pathogenesis of insulin
resistance (impaired IS) and type 2 diabetes. Results from con-
trolled and intervention studies permit a more specific assess-
ment of the effect of FA quality on IS.
Controlled and intervention studies
Using the previously described search criteria, we identified
forty-one articles assessing the role of dietary fat quality on glu-
cose metabolism. In general, these studies did not show
a differential effect of dietary FA quality on IS; however,
several methodological flaws may explain this conclusion. In
order to select those studies to be included in our analysis, we eval-
uated the quality of experimental designs based on the approach
used to evaluate IS (dependent variable), control of dietary fat
quality (independent variable) and other confounding variables.
Dependent variable: insulin sensitivity. A key factor
affecting data quality is the selection of the IS marker. Surrogate
measurements of IS based on fasting glycaemia and insulinae-
mia (i.e., homeostasis model assessment) are not recommended
for physiological or clinical studies since they explain no more
than 40 % of the IS variance observed in a population, and
,13 % of the IS variance in normal-weight subjects(19). Refer-
ence methods such as the euglycaemic–hyperinsulinaemic
clamp(20), insulin suppression test(21) and the frequently sampled
intravenous glucose tolerance test with the Minimal Model(22)
are considered reliable approaches to determine the degree of
IS. Achievement of a fully suppressed hepatic glucose pro-
duction is critical for interpretation of IS data using insulin infu-
sion methods; otherwise the degree of IS will be underestimated
unless hepatic glucose production is concomitantly measured. In
lean, non-diabetic individuals hepatic glucose production is fully
suppressed at plasma insulin concentration of about 60 mU/ml
(about 40 mU insulin/m2 per min or about 1 mU/kg body
weight per min); however in type 2 diabetic subjects, the insulin
dose needs to be increased at least 2-fold to observe a compar-
able effect(23,24).
Another relevant issue to assess dietary fat quality effect on
IS relates to the reproducibility of the IS measurement and
sample size required to demonstrate a significant effect. All
reference methods for assessing IS have an intra-individual
variation of about 15 %(21,25,26), thus an average change in
response to the dietary intervention equal or higher than this
value (1 SD) might be considered as biologically relevant.
Therefore, the sample size required to detect a difference
(by at least 1 SD) between interventions is sixteen subjects,
considering a type I error and power of 5 % and 80 %,
respectively. Studies aiming to detect a difference between
treatments lower than 1 SD will need higher sample size.
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Independent variable: quality of the fat intake.
Considering the potential interaction among various dietary
components, studies which modify dietary fat quality as the
single variable of interest are required to assess the effect of
fat quality on IS. This is more feasible in short-term (1–7 d)
studies; however, given that the magnitude of FA effects on
IS may be dependent on duration of exposure, the need for
appropriate assessment of dietary compliance is increased.
This limitation is usually ignored or underestimated in most
studies. In order to assure dietary compliance in free-living
people the following conditions should be met: (i) maintain
stable energy balance; (ii) maintain a fixed macronutrient
composition of dietary energy intake; (iii) monitor the achieve-
ment of the target fat intake of a given composition. A simple
strategy to evaluate energy balance is the recording of body
weight. This should not fluctuate if energy intake is matched
by energy expenditure. However, some studies do not even
report this simple body weight information. With respect to
macronutrient distribution of energy and dietary fat intake,
instructions are usually given to subjects on how to incorporate
the dietary changes. However, instructions are often difficult to
follow and in many cases total energy and/or macronutrient
intake may change since subjects tend to maintain their ad
libitum diet. For example, Summers et al. (27) provided dietary
instructions to modify SFA and PUFA intake for 5 weeks, rein-
forcing participants on an individual basis over the study period.
Upon analysis of food consumption records and body weight
changes the data were highly suggestive of a systematic under-
reporting of energy intake by an average of 1674 kJ/d and of
total fat intake by 40 g/d.
Some studies provide key food ingredients (main fat sources)
or provide scales to quantify consumption of specific foods.
These attempts to control dietary compliance are insufficient.
Controlled food consumption under direct supervision in an out-
patient setting is the preferred method to assure compliance.
In order to objectively verify dietary compliance in terms of
FA quality, changes in plasma or blood cell FA composition
have been used. To interpret results from this evaluation, the
following considerations should be kept in mind. First, changes
in tissue FA profile can occur within a range of dietary FA
intakes. Therefore, at best this is qualitative indicator of
changes in dietary fat. Second, FA compositional changes in
blood may not fully reflect the relevant cellular or subcellular
pools. Third, the change for serum and tissue phospholipids
subclasses, TAG or cholesterol esters are time dependent
according to turnover rates of the specific tissue pool and the
metabolism of the given FA(28 – 30). Finally, we need to
consider how the changes in FA profile expressed; in most
cases they are measured as percentage of total FA injected in
the gas chromatographer and not per unit of tissue weight or
plasma volume. Since the dietary intervention may modify
the total circulating or tissue fat content this may wrongly esti-
mate the true change.
Confounding variables. Multiple confounders may
obscure a true effect of FA on IS; these require a strict control,
particularly when dietary changes are subtle or in small mag-
nitude, as is often the case in long-term studies. Full control of
multiple confounders is nearly impossible but we consider that
the following factors are essential for a good study. Overall
health and nutritional status, age, customary dietary patterns,
alcohol consumption, physical activity level, gender, use of
contraceptives, menstrual status and phase of the cycle when
measurements are collected are the main confounding vari-
ables. Sub-clinical conditions such prediabetic state and
hyperlipidaemia should also be assessed. Actually, several
studies show an association between duration and quality of
sleep and metabolic indices(31). In addition, IS changes are
highly variable between subjects in response to the same
nutritional stimulus (i.e., fat overload). Emerging evidence
suggests that genetic polymorphisms are able to account in
part for this variability(32). Efforts to adequately account for
the confounding effects should provide stronger data where
more conclusive statements can arise.
Identifying the FA effect on IS may also depend on the
appropriateness of the data analysis and statistical testing for
covariates. For instance, as suggested by the KANWU multi-
center study(33), after splitting the group by the median energy
fat percentage, significant differences in IS according to fat
quality (SFA v. MUFA) were observed. The net result for
the MUFA effect was that the sub-group with low-fat intake
had a 20 % enhanced IS relative to a SFA diet, whereas no
MUFA-induced changes in IS were observed in the high-fat
intake subgroup. Unfortunately, lack of inclusion of other rel-
evant confounders (age, gender, nutritional status, degree of
IS, menopausal status, geographic location) in the statistical
model limit the application of this finding.
Study selection for analysis of effect of dietary fatty acid
quality on insulin sensitivity in human subjects. Based on
what has been presented in the previous section we attempted
to categorize and select studies according to the quality of the
experimental design. The criteria considered for study selec-
tion are shown in Table 1. Two authors (J. G. and E. D.) inde-
pendently applied the criteria for study selection. Additional
analysis included evaluation of strength and weakness of
each study. We considered as points of strength well-powered
studies (at least sixteen subjects in each group or intervention
period), with a crossover design and inclusion of washout
period; providing evidence of good or excellent dietary com-
pliance, body weight stability and control for menstrual
Table 1. Criteria for selection of studies evaluating effect of dietary fatty
acid quality on insulin sensitivity in human subjects
Criteria Detail
Fatty acid quality as
unique independent
variable
Diets with similar energy and macronutrient
content supplied according a random,
crossover/parallel design
Dietary compliance at
least fairly controlled
No changes in body weight indicating energy
balance in equilibrium
Controlled by at least one of these
strategies: diets prepared in metabolic
kitchen and consumed under
supervision; provision of the main fat
sources with defined nutrient and lipid
composition; continuous dietary
instructions and food records/capsule
counting supervised by dietitians;
blood/tissue fatty acid profile
determination
Insulin sensitivity
assessed using
reference methods
Evaluated with euglycaemic–
hyperinsulinaemic clamp, insulin
suppression test or frequently sampled
intravascular glucose tolerance test
with Minimal Model
Fatty acids and insulin sensitivity 473
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cycle as appropriate. Glucose disposal rate corrected for hepa-
tic glucose production was considered as additional strength in
studies in type 2 diabetic subjects.
From the total number of identified studies (n 41), fifteen
matched the proposed quality criteria. These studies are sum-
marized separately for non-diabetic subjects(30,33 – 40) (Table 2)
and type 2 diabetic subjects(27,41 – 45) (Table 3). Those studies
not selected for the analysis and reason for exclusion are
shown as supplementary material. Three out of the fifteen
studies reported a differential effect on IS, showing decreased
IS after SFA v. MUFA(33) or PUFA(27) diets; whereas
increased insulin resistance after fish oil supplementation
was observed in type 2 diabetic individuals(45). Also, we
observed that according to the strength and weakness analysis
(Table shown as supplementary material), the best rated study
is by Vessby et al. (33). This study reported a significant
decrease in IS of 10 % after consuming a SFA-enriched diet
for 12 weeks, whereas no change in IS was observed with
the MUFA-enriched diet. Fish oil v. olive oil supplementation
were additionally compared in this study; however, no differ-
ential effect on IS was found.
Potential mechanisms involved in fatty acid quality-
dependent insulin resistance
In human subjects, using vegetable fat (safflower or soya-
bean) emulsions infused intravenously(46 – 48) or hyperener-
getic, high-SFA diets it is possible to impair IS within few
days or even hours(49,50). In both conditions, intramyocellular
lipid content is increased which is causally related to
impaired IS(51,52), since specific lipid species (i.e., diacylgly-
cerols or ceramides) can activate specific serine
kinases(53 – 56). These kinases increase serine-phosphorylation
of critical insulin signaling proteins (i.e., insulin receptor sub-
strate 1) which reduce insulin-dependent GLUT-4 transloca-
tion and finally glucose uptake(52). Specific FA probably
induce these changes at different levels of cell function.
Change in FA cell membrane composition is one of the
most recurrent mechanisms. FA can modify membrane func-
tion by changing overall membrane fluidity, affecting mem-
brane thickness/volume, modifying lipid phase properties,
inducing changes in the membrane microenvironment, or by
interactions of specific lipid components with membrane pro-
teins(57,58). However, the limited evidence to support this idea
is based on weak associations between specific membrane FA
profile and the IS data derived from cross-sectional studies in
subjects with different metabolic states and poorly character-
ized diets(17,59 – 61). On the other hand, FA may affect intra-
cellular lipid balance based on its differential individual FA
oxidation rate(62 – 65) and ability to modify the binding of
the regulatory proteins (i.e., PPAR) to DNA response
elements involved in lipid metabolism(66 – 68). In animals,
Pan et al. (69) demonstrated differential 24 h [1-14C]a-linole-
nic oxidation rate and 14C muscle incorporation in rats fed
for 1 month with SFA, MUFA, and n-6 PUFA diets. The
highest 24 h 14CO2 recovery was found in the safflower-fed
group, followed by the olive oil and lard diet; whereas skel-
etal muscle 14C incorporation followed the inverse order.
Finally, FA may differentially affect inflammatory path-
ways(70), which are tightly related to impaired IS. For
example, toll-like receptor (TLR)-4-deficient mice (TLR-4
is important for mediating innate immune response to bac-
terial pathogens) have a much lower reduction of IS after
infusing a lipid emulsion compared to wild-type animals(71).
Interestingly, increased TLR-4-mediated cytokine generation
was observed after SFA (palmitic acid), but not n-3 PUFA
supplementation.
Discussion and conclusions
Human studies have failed to demonstrate a consistent differ-
ential effect of dietary fat quality on IS, which contrasts with
observation from animal studies, where n-6 PUFA in compari-
son to n-3 PUFA decrease IS(5,6). Several factors might
explain this disparate finding. Perhaps the simplest expla-
nation involves the differences in the fish oil and n-6 PUFA
dose used in animals as compared to human studies. In
human subjects, the maximal fish oil dose studied does not
exceed 20 g/d (about 0·25 g/kg body weight per d)(45) whereas
studies in rats used 3·4 g(5) and 20 g(6) fish oil/kg body weight
per d. After correcting these doses for differences in metabolic
rate, the fish oil administered to rats is between three and
twenty times greater than the maximal dose used in human
subjects. This is obtained after applying a scaling factor of
0·75; acceptable for comparisons among mammalian species
with different body mass(72). Then, for an 80 kg human subject
an approximately 4-fold lower metabolic rate than that of a
0·35 kg rat on a per kg basis is calculated; the equivalent
dose of 0·25 g fish oil/kg per d in a human subject corresponds
to 1 g/kg per d for the rat. When the same estimation is done
for n-6 PUFA, the doses used in human subjects and rats are
much closer, since large amount of n-6 PUFA are present in
most Western diets.
In addition, the effect of fish oil on IS has been mainly
assessed in individuals with type 2 diabetes (Table 3). Perhaps
at this stage of metabolic impairment, glucose homeostasis
may not be capable of an improvement even when a large
dose of fish oil is provided. In non-diabetic individuals the
effects of fish oil on IS has been scarcely evaluated. In a
well-powered long-term study, diets enriched in SFA or
MUFA were compared(33). Additionally, each diet was sup-
plemented with fish oil or olive oil (placebo). As commented
before, significant differences in IS between SFA and MUFA
diets were found; however fish oil supplementation did not
modify IS (see Table 2).
The potential protective effect of n-3 PUFA on IS in human
subjects might require higher fish-oil doses associated with
lower n-6 PUFA content. Studies in a healthy and diabetic
population using diets with low absolute amounts of n-6
PUFA should be preferred in order to adequately test the
potential effect of fish oil on IS. Fat sources such as linseed
oil, which are rich in a-linolenic acid (.55 % of total FA)
can be used to reduce amount of n-6 FA with the aim to
achieve a dietary n-6 : n-3 PUFA ratio lower than 4:1 but as
close to 1:1 as possible. This n-6:n-3 PUFA ratio is similar
to that observed in traditional Asian diets considering the
use of both marine and land sources of n-3 PUFA.
There is also a need to distinguish between fish oil and
highly-unsaturated n-3 FA (EPA and DHA), since the
amount of EPA and DHA commonly present in fish oil is
about one third of the total FA content and the relative balance
between EPA and DHA may also vary. To the best of our
J. E. Galgani et al.474
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Table 2. Effect of dietary fat quality intervention on insulin sensitivity in non-type 2 diabetic subjects
Study Subjects (n for IS data) Design Time Dietary intervention IS method Outcome for IS*
Schwab et al. (1995)(34) Healthy, young, non-obese
women (n 11)
Crossover, random. 2 week diet
control before interventions
4 weeks Fat % 38. Diets high in lauric
(5%) or palmitic (12%) acids
FSIVGTT with MinMod
program
No change
Lauric: 4·5 (SD 0·5)
Palmitic: 4·8 (SD 0·6)
Fasching et al. (1996)(35) Healthy, young, non-obese
men (n 8)
Crossover, random. Washout
period for 2 weeks
1 week Fat % 55. Diets high in SFA
(30%) or PUFA (26%)
Euglycemic clamp
(190mU/m2 per min)
No change
SFA: 9·7 (SD 0·8)
PUFA: 9·8 (SD 0·9)
Louheranta et al. (1998)(36) Healthy, young, non-obese
women (n 14)
Crossover, random. 2 week
basal diet before each
intervention
4 weeks Fat % 40. Diets high in oleic
(19%) or stearic (19%) acids
FSIVGTT with MinMod
program
No change
Oleic: 5·2 (SD 1·6)
Stearic: 5·4 (SD 1·9)
Louheranta et al. (1999)(37) Healthy, young, non-obese
women (n 14)
Crossover, random. 2 week basal
diet prior to each period
4 weeks Fat % 37. Diets high in trans-
(5%) or cis- (19%) MUFA
FSIVGTT with MinMod
program
No change
trans-MUFA: 5·1 (SD 0·4)
cis-MUFA: 4·8 (SD 0·4)
Lovejoy et al. (2002)(38) Healthy, young, non-obese
subjects both sexes (n 25)
Crossover, random, double blind.
Washout period for 2 weeks
4 weeks Fat % 27. Diets high in trans- (7%),
cis- (15%) MUFA or SFA (11%)
FSIVGTT with MinMod
program
No change
trans-MUFA: 3·4 (SD 0·3)
cis-MUFA: 3·4 (SD 0·3)
SFA: 3·2 (SD 0·3)
Andersson et al. (2002)(30) Non-diabetic subjects both
sexes (n 32)
Parallel, random, single blind 3 months Fat % 37. Diets high in MUFA (21%)
or SFA (18%). Each group
supplemented with 3·6 g/d n-3 FA
(2·4 g EPA þ DHA) or olive oil
FSIVGTT with MinMod
program
No change (values
not reported)
Brady et al. (2004)(39) Healthy, lean and obese
men (n 14)
Parallel, random, double blind 12 weeks Fat % 37. Diets high in MUFA
(15%) or n-6 PUFA (10%)
FSIVGTT with MinMod
program
No change
MUFA: 2·8 (SD 0·7)
n-6 PUFA: 2·0 (SD 0·4)
Vessby et al. (2001)(33) Non-diabetic subjects
both sexes (n 162)
Multicenter study. Parallel,
random, single blind
3 months Fat % 37. Diets high in MUFA (21%)
or SFA (18%). Each group
supplemented with 3·6 g/d n-3
FA (2·4 g EPA þ DHA) or olive oil
FSIVGTT with MinMod
program
Lower after SFA (P¼0·03)
No change with fish oil
MUFA: 4·9; SFA: 3·7
(SD not reported)
Toft et al. (1995)(40) Non-treated hypertensive,
non-diabetic subjects
both sexes (78)
Parallel, random,
double blind
16 weeks Fat % not reported. Supplementation
with 4 g/d fish oil (3·4 g
EPA þ DHA) or corn oil
Euglycemic clamp
(40mU/m2 per min)
No change
Fish: 0·07; Placebo: 0·07
(SD not reported)
IS, insulin sensitivity; FSIVGTT with MinMod, frequently sampled intravascular glucose tolerance test with Minimal Model.
* IS units are different in each study and these have been not included in the table.
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Table 3. Effect of dietary fat quality intervention on insulin sensitivity in type 2 diabetic subjects
Study Subjects (n for IS data) Design Time Dietary intervention IS method Outcome for IS*
Summers et al. (2002)(27) Non-obese, obese and
type 2 diabetic (n 17)
Crossover, random.
No washout
period included
5 weeks Fat % 42 in SFA diet and 34%
in PUFA diet. Diets enriched in
SFA (21%) or PUFA (9%)
Euglycemic clamp
(40mU/m2 per min)
Higher after PUFA
SFA: 0·51 (SD 0·08)
PUFA: 0·64 (SD 0·10)
(P¼0·02)
Borkman et al. (1989)(41) Type 2 diabetic subjects
both sexes (n 10)
Crossover, random, double
blind. Washout period
for 3weeks
3 weeks Fat % 37. Supplementation with
10 g/d fish oil (3 g EPA
þ DHA) or safflower oil
Euglycemic clamp (1·1mU/kg
per min) with HGP correction
No change
Fish: 21·5 (SD 3·5)
Placebo: 21·2 (SD 3·8)
Luo et al. (1998)(42) Type 2 diabetic,
hypertriacylglycerolaemic
men (n 10)
Crossover, random, double
blind. Washout period
for 2months
8 weeks Fat % 44. Supplementation
with 6 g/d fish oil (1·8 g
EPA þ DHA) or sunflower oil
Euglycemic clamp with 2 insulin
doses (40 and 250mU/m2
per min) and HGP correction
No change
Low-insulin: Fish 3·3
(SD 0·2); Placebo
3·8 (SD 0·5)
High-insulin: Fish 8·1
(SD 0·9); Placebo
8·8 (SD 0·8)
Boberg et al. (1992)(43) Type 2 diabetic both
sexes (n 14)
Crossover, random, double
blind. No washout
period included
8 weeks Dietary fat % not indicated.
Supplementation with 10 g/d
fish oil (3 g EPA þ DHA) or olive oil
Euglycemic clamp (not
indicated insulin dose)
No change
Fish 4·7; Placebo 4·9
(SD not reported)
Rivellese et al. (1996)(44) Type 2 diabetic both
sexes (n 16)
Parallel, random,
double blind
6 months Fat % 30. Supplementation with fish
oil (first 2mo 3·2 g/d (2·6 g EPA þ
DHA) and last 4mo 2·1 g/d
(1·7 g EPA þ DHA)) or olive oil
Euglycemic clamp
(2mU/kg per min)
No change
Fish 4·0 (SD 0·5);
Placebo 4·1 (SD 0·5)
Mostad et al. (2006)(45) Type 2 diabetic both
sexes (n 26)
Parallel, random,
double blind
9 weeks Fat % 38. Supplementation
with 18ml/d fish oil (5 g
EPA þ DHA) or corn oil
Euglycemic clamp
(40mU/m2 per min)
Lower after fish oil
(values not reported)
(P¼0·049)
IS, insulin sensitivity; HGP, hepatic glucose production.
* IS units are different in each study and these have been not included in the table.
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knowledge only one study has assessed the effect of EPA and
DHA on IS separately(73); however, the lack of a reliable
marker of IS in this study does not permit an adequate
conclusion.
The time to respond in terms of IS to the intervention may
also be critical in explaining the lack of differential effect of
fat quality on IS in human subjects. From the available data
it is unclear what is the required time to increase the chances
of finding a differential effect on IS relating to the FA quality.
At present, well-supported effects have been demonstrated
after 12 weeks of intervention(33), suggesting that changes in
plasma and/or sub-cellular FA composition might be critical.
On the other hand, it is well known that even after short-
time periods, SFA-enriched diets (days)(49,50) or vegetable
fat-based lipid infusions (hours)(46 – 48) are able to reduce insu-
lin action in human subjects. To date, only two studies have
assessed the short-term effect of FA quality on IS; however,
small sample sizes(35) or inappropriate assessment of IS(74)
do not permit firm conclusions to be drawn. Thus, a well-pow-
ered, controlled short-term intervention should not be
excluded as a suitable approach to assess dietary fat quality
effect on IS in human subjects.
Finally, the realization that not all fats are the same is by no
means new; however, we are just beginning to unravel the
physiologic and possibly therapeutic effects of specific FA.
These nutrients should no longer be considered solely as a
source of energy but should rather be acknowledged as
potent regulators of intermediary metabolism, and possible
contributors to the regulation of glucose homeostasis in both
type 2 diabetic and non-diabetic individuals.
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